Two IgG-type cold auto-agglutinins causing transiently occurring haemolytic anaemia in children are described. The antibodies were limited to the IgG fraction obtained by DEAE cellulose chromatography and were resistant to 2-mercaptoethanol treatment. One auto-agglutinin reacted ‘incompletely’ (in the en-zyme test), the other reacted ‘completely’ and its reactivity was furthermore abolished by treatment of red cells with proteolytic enzymes, but not with neuraminidase. Because of the inactivation of the corresponding antigen on red cells by proteolytic enzymes, this receptor belongs to the Pr complex, but it can be distinguished from Pr(1)/Pr(2), through its resistance to neuraminidase. Therefore a new symbol ‘Pr(a)’ is proposed. Based on these findings an immunochemical classification for antigens corresponding to cold auto-antibodies is given and a new nomenclature of the antigens which are inactivated by proteases is proposed depending on their determination or nondetermination by neuraminic acid.

Keywords:
Cold auto-antibodies, IgG-type agglutinins, Pr (HD) antigens, Proteolytic enzymes, Neuraminic acid
This content is only available via PDF.
1971
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.